- Home
- PETZ vs NXTC Comparison
PETZ vs NXTC Comparison
Compare PETZ & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- NXTC
- Stock Information
- Founded
- PETZ 2002
- NXTC 2015
- Country
- PETZ China
- NXTC United States
- Employees
- PETZ N/A
- NXTC N/A
- Industry
- PETZ Steel/Iron Ore
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- NXTC Health Care
- Exchange
- PETZ Nasdaq
- NXTC Nasdaq
- Market Cap
- PETZ 11.3M
- NXTC 13.0M
- IPO Year
- PETZ 2017
- NXTC 2019
- Fundamental
- Price
- PETZ $1.06
- NXTC $11.84
- Analyst Decision
- PETZ
- NXTC Strong Buy
- Analyst Count
- PETZ 0
- NXTC 2
- Target Price
- PETZ N/A
- NXTC $25.50
- AVG Volume (30 Days)
- PETZ 15.9K
- NXTC 58.9K
- Earning Date
- PETZ 04-28-2025
- NXTC 11-06-2025
- Dividend Yield
- PETZ N/A
- NXTC N/A
- EPS Growth
- PETZ N/A
- NXTC N/A
- EPS
- PETZ 0.26
- NXTC N/A
- Revenue
- PETZ $563,726.00
- NXTC N/A
- Revenue This Year
- PETZ N/A
- NXTC N/A
- Revenue Next Year
- PETZ N/A
- NXTC N/A
- P/E Ratio
- PETZ $5.09
- NXTC N/A
- Revenue Growth
- PETZ 74664.72
- NXTC N/A
- 52 Week Low
- PETZ $0.65
- NXTC $2.69
- 52 Week High
- PETZ $1.68
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- PETZ 47.85
- NXTC 80.98
- Support Level
- PETZ $1.01
- NXTC $6.23
- Resistance Level
- PETZ $1.13
- NXTC $13.17
- Average True Range (ATR)
- PETZ 0.07
- NXTC 1.01
- MACD
- PETZ -0.01
- NXTC 0.58
- Stochastic Oscillator
- PETZ 26.00
- NXTC 83.02
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.